Expression, regulation and function of intestinal drug transporters: an update

Abstract Although oral drug administration is currently the favorable route of administration, intestinal drug absorption is challenged by several highly variable and poorly predictable processes such as gastrointestinal motility, intestinal drug solubility and intestinal metabolism. One further determinant identified and characterized during the last two decades is the intestinal drug transport that is mediated by several transmembrane proteins such as P-gp, BCRP, PEPT1 and OATP2B1. It is well-established that intestinal transporters can affect oral absorption of many drugs in a significant manner either by facilitating their cellular uptake or by pumping them back to gut lumen, which limits their oral bioavailability. Their functional relevance becomes even more apparent in cases of unwanted drug-drug interactions when concomitantly given drugs that cause transporter induction or inhibition, which in turn leads to increased or decreased drug exposure. The longitudinal expression of several intestinal transporters is not homogeneous along the human intestine, which may have functional implications on the preferable site of intestinal drug absorption. Besides the knowledge about the expression of pharmacologically relevant transporters in human intestinal tissue, their exact localization on the apical or basolateral membrane of enterocytes is also of interest but in several cases debatable. Finally, there is obviously a coordinative interplay of intestinal transporters (apical–basolateral), intestinal enzymes and transporters as well as intestinal and hepatic transporters. This review aims to give an updated overview about the expression, localization, regulation and function of clinically relevant transporter proteins in the human intestine.

[1]  C. Beglinger,et al.  MAPPING OF MULTIDRUG RESISTANCE GENE 1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN ISOFORM 1 TO 5 mRNA EXPRESSION ALONG THE HUMAN INTESTINAL TRACT , 2005, Drug Metabolism and Disposition.

[2]  Werner Weitschies,et al.  Disposition and sterol‐lowering effect of ezetimibe are influenced by single‐dose coadministration of rifampin, an inhibitor of multidrug transport proteins , 2006, Clinical pharmacology and therapeutics.

[3]  I. Gómez-Orellana Strategies to improve oral drug bioavailability , 2005, Expert opinion on drug delivery.

[4]  X. Chu,et al.  Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development , 2014, Drug Metabolism and Disposition.

[5]  Jeffrey C Stevens,et al.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  M. Pocard,et al.  Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.

[7]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[8]  T. Habuchi,et al.  Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients , 2008, Therapeutic drug monitoring.

[9]  T. Thalhammer,et al.  Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): impact on growth of ZR-75-1 breast cancer cells. , 2014, Molecular nutrition & food research.

[10]  Takashi Baba,et al.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. , 2012, Analytical chemistry.

[11]  M. Miksits,et al.  Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1 , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  S. Härtter,et al.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.

[13]  J. Nezu,et al.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. , 2000, Biochemical and biophysical research communications.

[14]  Shobha Bhattachar,et al.  The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.

[15]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  C. Gröer,et al.  Mass Spectrometry-Based Targeted Proteomics as a Tool to Elucidate the Expression and Function of Intestinal Drug Transporters , 2013, The AAPS Journal.

[17]  X. Jia,et al.  Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. , 2005, Current drug metabolism.

[18]  Sheila Annie Peters,et al.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models , 2016, Clinical Pharmacokinetics.

[19]  H. Kroemer,et al.  Intestinal expression of P‐glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans , 2006, Clinical pharmacology and therapeutics.

[20]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[21]  M. Nauck,et al.  Compartment‐Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo , 2012, Clinical pharmacology and therapeutics.

[22]  M. Okuda,et al.  MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. , 2014, Pharmacology & therapeutics.

[23]  C. Klaassen,et al.  Regulation of hepatic transporters by xenobiotic receptors. , 2005, Current drug metabolism.

[24]  R. Neubert,et al.  Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.

[25]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[26]  Christer Tannergren,et al.  Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Bradley L Urquhart,et al.  Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.

[28]  T. Andersson,et al.  Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects , 2013, Clinical pharmacology and therapeutics.

[29]  R. Kim,et al.  Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.

[30]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[31]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[32]  Y Zhang,et al.  The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.

[33]  D. Keppler,et al.  Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs , 2008, Expert opinion on drug metabolism & toxicology.

[34]  B. Stieger,et al.  Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene , 2012, Journal of Translational Medicine.

[35]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.

[36]  M. Fromm,et al.  Transporter‐Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.

[37]  Y. Lai,et al.  Quantitative Targeted Proteomics for Membrane Transporter Proteins: Method and Application , 2014, The AAPS Journal.

[38]  Michael D. Johnson,et al.  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.

[39]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[40]  J. Mostertz,et al.  Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers , 2012, Clinical pharmacology and therapeutics.

[41]  X. Ming,et al.  Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. , 2016, Journal of pharmaceutical sciences.

[42]  D. Keppler The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in Conjugated Hyperbilirubinemia , 2014, Drug Metabolism and Disposition.

[43]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[44]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[45]  A. Kong,et al.  Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.

[46]  M. H. Ensom,et al.  Pharmacokinetic Effects of Bariatric Surgery , 2012, The Annals of pharmacotherapy.

[47]  Erik Sjögren,et al.  Direct In Vivo Human Intestinal Permeability (Peff ) Determined with Different Clinical Perfusion and Intubation Methods. , 2015, Journal of pharmaceutical sciences.

[48]  D. Tibboel,et al.  Human Intestinal PEPT1 Transporter Expression and Localization in Preterm and Term Infants , 2016, Drug Metabolism and Disposition.

[49]  Li Di,et al.  Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. , 2014, Molecular pharmaceutics.

[50]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[51]  H. Schoemaker,et al.  The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay. , 1993, British journal of clinical pharmacology.

[52]  M. Coughtrie,et al.  Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. , 2012, Biochemical pharmacology.

[53]  M. Hediger,et al.  Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. , 2013, Molecular aspects of medicine.

[54]  I. Cascorbi,et al.  MicroRNAs and their relevance to ABC transporters. , 2014, British journal of clinical pharmacology.

[55]  T. Terasaki,et al.  Large‐scale multiplex absolute protein quantification of drug‐metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH‐MS: Comparison with MRM/SRM and HR‐MRM/PRM , 2016, Proteomics.

[56]  Curtis D. Klaassen,et al.  Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation , 2010, Pharmacological Reviews.

[57]  Michael Zschiesche,et al.  Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.

[58]  W. Kramer Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery , 2011, Biological chemistry.

[59]  S. Cole,et al.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.

[60]  B. Hirst,et al.  The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[61]  Leslie Z Benet,et al.  Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems , 2006, Journal of Pharmacology and Experimental Therapeutics.

[62]  W. H. Barr,et al.  Differential absorption of amoxicillin from the human small and large intestine , 1994, Clinical pharmacology and therapeutics.

[63]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[64]  S. Oswald,et al.  Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. , 2015, Molecular pharmaceutics.

[65]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[66]  R. Kim,et al.  Nuclear receptors and drug disposition gene regulation. , 2005, Journal of pharmaceutical sciences.

[67]  A. Mitra,et al.  Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines. , 2013, International journal of pharmaceutics.

[68]  J. Nezu,et al.  Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.

[69]  L Landmann,et al.  Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.

[70]  Huijun Sun,et al.  Construction, identification and application of HeLa cells stably transfected with human PEPT1 and PEPT2 , 2012, Peptides.

[71]  Wilhelm Kirch,et al.  Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability , 2005, Clinical pharmacology and therapeutics.

[72]  C. Beglinger,et al.  Breast Cancer Resistance Protein and P-Glycoprotein Expression in Patients with Newly Diagnosed and Therapy-Refractory Ulcerative Colitis Compared with Healthy Controls , 2008, Digestion.

[73]  Leslie Z Benet,et al.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.

[74]  M. Fromm,et al.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[75]  J. Wiśniewski,et al.  The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition. , 2016, Journal of pharmaceutical sciences.

[76]  M. Hediger,et al.  The ABCs of membrane transporters in health and disease (SLC series): Introduction , 2013, Molecular aspects of medicine.

[77]  Michael Zschiesche,et al.  The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen , 2005, Pharmaceutical Research.

[78]  M. Eichelbaum,et al.  A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression , 2005, Biological chemistry.

[79]  J. Unadkat,et al.  Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics , 2014, The AAPS Journal.

[80]  M. Fromm,et al.  The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.

[81]  G. Kullak-Ublick,et al.  Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. , 2012, Translational research : the journal of laboratory and clinical medicine.

[82]  Oliver Burk,et al.  Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.

[83]  Jackie C Bloomer,et al.  Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie” , 2009, Drug Metabolism and Disposition.

[84]  P. Artursson,et al.  PREDOMINANT CONTRIBUTION OF ORGANIC ANION TRANSPORTING POLYPEPTIDE OATP-B (OATP2B1) TO APICAL UPTAKE OF ESTRONE-3-SULFATE BY HUMAN INTESTINAL CACO-2 CELLS , 2006, Drug Metabolism and Disposition.

[85]  H. Lennernäs Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[86]  J. Beijnen,et al.  Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides , 2007, Molecular Pharmacology.

[87]  P. Artursson,et al.  Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1) , 2007, Inflammatory bowel diseases.

[88]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[89]  X. Ming,et al.  Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. , 2011, Molecular pharmaceutics.

[90]  H. Kroemer,et al.  Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[91]  C. Paulusma,et al.  Oral Availability of Cefadroxil Depends on ABCC3 and ABCC4 , 2012, Drug Metabolism and Disposition.

[92]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[93]  X. Chu,et al.  Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics , 2015, Drug Metabolism and Disposition.

[94]  P. Artursson,et al.  Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[95]  I. Tamai,et al.  Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. , 2011, Journal of pharmaceutical sciences.

[96]  S. Vavricka,et al.  Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract , 2007, Drug Metabolism and Disposition.

[97]  Fabian Müller,et al.  Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects , 2013, Pharmacological Reviews.

[98]  C. Beglinger,et al.  Changes in mRNA Expression Levels of Solute Carrier Transporters in Inflammatory Bowel Disease Patients , 2009, Drug Metabolism and Disposition.

[99]  L Zhang,et al.  Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[100]  D. Rosskopf,et al.  Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1 , 2008, Pharmacogenetics and genomics.

[101]  A Rostami-Hodjegan,et al.  Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.

[102]  J. Staudinger,et al.  Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver , 2013, Drug metabolism reviews.

[103]  A. Schinkel,et al.  Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2 , 2009, Drug Metabolism and Disposition.

[104]  W. Sadee,et al.  Intra- and Interindividual Variabilities of Valacyclovir Oral Bioavailability and Effect of Coadministration of an hPEPT1 Inhibitor , 2003, Antimicrobial Agents and Chemotherapy.

[105]  L. Trahms,et al.  Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[106]  Gerd Mikus,et al.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. , 2003, British journal of clinical pharmacology.

[107]  I. Kapetanovic,et al.  Glucuronidation of trans‐resveratrol by human liver and intestinal microsomes and UGT isoforms , 2006, The Journal of pharmacy and pharmacology.

[108]  Olivier Fardel,et al.  Differential Regulation of Sinusoidal and Canalicular Hepatic Drug Transporter Expression by Xenobiotics Activating Drug-Sensing Receptors in Primary Human Hepatocytes , 2006, Drug Metabolism and Disposition.

[109]  H. Colom,et al.  The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. , 2012, Archives of biochemistry and biophysics.

[110]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[111]  S. Misaka,et al.  Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy Subjects , 2014, Clinical pharmacology and therapeutics.

[112]  Paul D. Martin,et al.  Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure , 2016, Drug Metabolism and Disposition.

[113]  Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects , 2012, European Journal of Clinical Pharmacology.

[114]  Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases , 2015, Pharmaceutical Research.

[115]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[116]  Leslie Z Benet,et al.  Intestinal drug transporters: an overview. , 2013, Advanced drug delivery reviews.

[117]  A. Ungell,et al.  Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[118]  J. Brockmöller,et al.  Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. , 2013, Biochemical pharmacology.

[119]  P. Artursson,et al.  Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[120]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[121]  J. Verschoor,et al.  Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. , 1987, Arzneimittel-Forschung.

[122]  D. Bailey Fruit juice inhibition of uptake transport: a new type of food-drug interaction. , 2010, British journal of clinical pharmacology.

[123]  G. Fricker,et al.  Establishment of optimized MDCK cell lines for reliable efflux transport studies. , 2014, Journal of pharmaceutical sciences.

[124]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[125]  W. Kirch,et al.  P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.

[126]  D. Lütjohann,et al.  Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. , 2010, Journal of pharmaceutical sciences.

[127]  T. Nakanishi,et al.  OATP transporter-mediated drug absorption and interaction. , 2013, Current opinion in pharmacology.

[128]  M. Paine,et al.  P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.

[129]  Bruno Stieger,et al.  Organic anion-transporting polypeptides. , 2014, Current topics in membranes.

[130]  P. Dawson Role of the intestinal bile acid transporters in bile acid and drug disposition. , 2011, Handbook of experimental pharmacology.

[131]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[132]  W. Kirch,et al.  Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.

[133]  A. Rostami-Hodjegan,et al.  Caco‐2 cells – expression, regulation and function of drug transporters compared with human jejunal tissue , 2017, Biopharmaceutics & drug disposition.

[134]  H. Eichler,et al.  Comparative Target Site Pharmacokinetics of Immediate‐ and Modified‐Release Formulations of Cefaclor in Humans , 2002, Journal of clinical pharmacology.

[135]  H. Lennernäs,et al.  Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. , 2007, Molecular pharmaceutics.

[136]  K. Maeda,et al.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.

[137]  A. Reichel,et al.  Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats , 2008, Drug Metabolism and Disposition.

[138]  P. Langguth,et al.  Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[139]  T. Baillie,et al.  Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.

[140]  P. Artursson,et al.  Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.

[141]  N. Hosten,et al.  Characterization of the Intestinal and Hepatic Uptake/Efflux Transport of the Magnetic Resonance Imaging Contrast Agent Gadolinium-Ethoxylbenzyl-Diethylenetriamine-Pentaacetic Acid , 2014, Investigative radiology.

[142]  K. Brouwer,et al.  Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes , 2013, Molecular Pharmacology.

[143]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[144]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[145]  T. Nakanishi,et al.  Interaction of Drug or Food with Drug Transporters in Intestine and Liver. , 2015, Current drug metabolism.

[146]  M. Ostrowski,et al.  Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. , 2014, Molecular pharmaceutics.

[147]  Maria Backlund,et al.  Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. , 2016, Journal of pharmaceutical sciences.

[148]  M. Brandsch Drug transport via the intestinal peptide transporter PepT1. , 2013, Current opinion in pharmacology.

[149]  H. Zimdahl,et al.  International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms , 2013, Clinical pharmacology and therapeutics.

[150]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[151]  M. Eichelbaum,et al.  Effects of rifampicin on global gene expression in human small intestine , 2007, Pharmacogenetics and genomics.

[152]  I. Cascorbi,et al.  Down-Regulation of ATP-Binding Cassette C2 Protein Expression in HepG2 Cells after Rifampicin Treatment Is Mediated by MicroRNA-379 , 2011, Molecular Pharmacology.

[153]  S. Härtter,et al.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. , 2012, British journal of clinical pharmacology.